Skip to main content
. Author manuscript; available in PMC: 2022 Feb 17.
Published in final edited form as: Clin Exp Hypertens. 2020 Oct 18;43(2):175–180. doi: 10.1080/10641963.2020.1836191

Figure 2: Effect of L-buthionine sulfoximine (BSO) and ML385 treatment on inflammatory cytokines in renal cortical homogenates.

Figure 2:

(a) IL-1β and (b) IL-10 levels were measured in pg/mg protein in control, mice kept on tap water; BSO), mice provided with 10 mmol/L BSO; ML385, mice provided with 10 mg/kg body weight/day of ML385; BSO+ML385, mice provided with both BSO and ML385.

Data are expressed as means ± SE of n=6 mice/group. *P<0.05 vs. control and #P<0.05 vs. BSO.

HHS Vulnerability Disclosure